Prof. Paul Herrling

Professor Paul Herrling was Head of Corporate Research at Novartis. He is also Chairman of the Board of the Novartis Institute for Tropical Diseases in Singapore, an endeavor to advance medical research in the area of tropical infectious diseases, which historically have received little drug-research funding.

Prior to this,  Paul Herrling was Head of Global Research at Novartis Pharma and a member of the Pharma Executive Committee (PEC).

Pr Herrling is member of the Board of the Genomics Institute of the Novartis Research Foundation in La Jolla California and he serves on the boards of several other research institutions.

Paul Herrling is also Professor of Drug Discovery Science at the University of Basel, Switzerland. He obtained his doctorate in 1975 at the University of Zurich and was a post-doctorate fellow at the Neuropsychiatric Institute at the University of California, Los Angeles (UCLA).

In addition to a number of scientific editing activities, he serves on several boards, most notably: he is Vice-President of the Board of the ETHs (Swiss Federal Institutes of Technology), Bern, and on the Scientific Advisory Committee of H3D Cape Town University.